---
title: "Zhongheng Group: Plans to repurchase shares for 300 million to 500 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234042028.md"
description: "Zhongheng Group plans to repurchase shares for between 300 million and 500 million yuan, with a repurchase price not exceeding 3.8 yuan per share. This repurchase will be used for cancellation and reduction of registered capital, with an expected number of repurchased shares ranging from 78.9474 million to 132 million shares, accounting for 2.35%-3.92% of the total share capital. The repurchase period will not exceed 6 months from the date of approval by the shareholders' meeting, with funding sourced from self-owned funds or self-raised funds, aimed at enhancing investor confidence and promoting a reasonable return of stock value"
datetime: "2025-04-01T10:37:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234042028.md)
  - [en](https://longbridge.com/en/news/234042028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234042028.md)
generator: "portal-rs"
---

# Zhongheng Group: Plans to repurchase shares for 300 million to 500 million yuan

Zhongheng Group announced that the company plans to repurchase shares with funds not less than 300 million yuan and not exceeding 500 million yuan, with a repurchase price not exceeding 3.8 yuan per share. All repurchased shares will be used for cancellation and reduction of the company's registered capital, with an estimated repurchase quantity of 78.9474 million shares to 132 million shares, accounting for 2.35%-3.92% of the company's total share capital. The repurchase period will not exceed 6 months from the date of approval by the shareholders' meeting, with funding sourced from the company's own funds or self-raised funds. The repurchase aims to enhance investor confidence, promote the reasonable return of stock value, and reduce registered capital

### Related Stocks

- [600252.CN](https://longbridge.com/en/quote/600252.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [VeriSilicon reports 91% first-half revenue growth as AI orders reach 90%](https://longbridge.com/en/news/296183434.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**